Tabulate side effects of phenytoin, phenobarbitone,carbamazipine,Na valproate,midozolam
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive data from multiple authoritative textbooks. Let me compile the complete table.
Side Effects of Major Antiepileptic Drugs
Here is a comprehensive tabulation drawn from Harrison's Principles of Internal Medicine (22nd Ed.), Kaplan & Sadock's Synopsis of Psychiatry, Adams & Victor's Neurology, and Goldman-Cecil Medicine.
Overview Table
| System / Effect | Phenytoin | Phenobarbitone | Carbamazepine | Sodium Valproate | Midazolam |
|---|---|---|---|---|---|
| CNS - Dose-related | Nystagmus, ataxia, slurred speech, diplopia, dizziness, mental confusion, motor twitching | Sedation (adults), hyperactivity (children), cognitive impairment, lethargy | Ataxia, drowsiness, diplopia/blurred vision, dizziness, task-performance impairment | Tremor, sedation, ataxia | Sedation, psychomotor impairment, amnesia, dizziness |
| CNS - Behavioural | Insomnia, transient nervousness, headache | Irritability, mood changes, behavioural disturbance | -- | -- | Paradoxical agitation/delirium (especially elderly) |
| CNS - Movement disorder | Dyskinesias (rare, phenothiazine-like) | -- | -- | -- | -- |
| Respiratory | Cardiovascular/respiratory depression at toxic IV doses | Respiratory depression (overdose) | -- | -- | Dose-related respiratory depression and apnea (especially with opioids); synergistic with co-administered CNS depressants |
| Cardiovascular | Hypotension, cardiac dysrhythmias (especially IV), contraindicated in 2nd/3rd degree AV block | -- | Decreased cardiac conduction; caution in cardiac disease; rare: immune myocarditis | -- | Mild hypotension (alone); significant hypotension with opioids |
| GI | Nausea, vomiting (less common) | -- | Nausea, vomiting, gastric distress, constipation, diarrhea, anorexia | GI upset (less with delayed-release formulation), nausea, vomiting | Nausea, vomiting (less common) |
| Haematological | Thrombocytopenia, leukopenia, agranulocytosis, pancytopenia, aplastic anaemia (rare) | Megaloblastic anaemia (long-term, folate-related) | Leukopenia (1-2%), aplastic anaemia, agranulocytosis (1:125,000); monitor CBC at 3, 6, 9, 12 months | Bone marrow suppression (reversible, rare) | -- |
| Hepatic | Elevated alkaline phosphatase, GGT | Enzyme induction (hepatic cytochrome P450) | Hepatitis (transaminase elevation), cholestasis (elevated bilirubin/ALP); fatal hepatic failure if reintroduced | Fatal hepatotoxicity (idiosyncratic; highest risk children <2 yrs); avoid in pre-existing liver disease | Prolonged half-life with CYP3A4 inhibitors (azole antifungals, HIV protease inhibitors, CCBs) |
| Skin | Maculopapular rash, Stevens-Johnson syndrome (rare) | Morbilliform rash | Maculopapular rash (10-15% within 3 weeks), Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis | Rash (lower risk than CBZ after 2 months) | -- |
| Metabolic / Endocrine | Hyperglycemia; elevated serum glucose (diabetes); decreased thyroxine | Osteoporosis (CYP P450 induction → ↓ vitamin D) | Hyponatremia, SIADH-like picture (water intoxication); no significant weight gain | Weight gain, hyperandrogenism, menstrual irregularities, polycystic ovary-like syndrome | -- |
| Cosmetic (long-term) | Gingival hyperplasia, hirsutism, coarsening of facial features, gynecomastia | -- | -- | Alopecia (hair loss), weight gain | -- |
| Bone | Osteoporosis (CYP induction → ↓ vitamin D) | Osteoporosis | Osteoporosis | Elevated cholesterol (lesser effect) | -- |
| Renal / Electrolyte | -- | -- | Hyponatremia, water intoxication (esp. elderly); also has antidiuretic effect (occasionally used for diabetes insipidus) | -- | -- |
| Psychiatric | -- | Depression, cognitive slowing | -- | -- | Delirium in elderly; paradoxical excitation |
| Lymphatic | Lymphadenopathy, pseudolymphoma, Hodgkin's disease (rare, long-term) | -- | -- | -- | -- |
| Teratogenicity | Congenital malformations ("fetal hydantoin syndrome"); neonatal bleeding (↓ vitamin K-dependent factors) | -- | Cleft palate, fingernail hypoplasia, microcephaly, spina bifida | Neural tube defects; highest rate of adverse fetal outcome (~20%); teratogenic | Potential fetal harm with prolonged exposure |
| Dependence / Tolerance | -- | Physical dependence; tolerance; withdrawal seizures on abrupt cessation | -- | -- | Tolerance with chronic use; psychological and physical dependence |
| Drug interactions | Levels raised by: amiodarone, cimetidine, fluoxetine, INH, estrogens. Levels lowered by: carbamazepine, chronic alcohol | Induces CYP enzymes; accelerates metabolism of many drugs | Auto-induction of own metabolism; inhibits lamotrigine; interacts with lithium | Inhibits lamotrigine metabolism (doubles lamotrigine half-life); valproate levels affected by carbamazepine | CYP3A4 substrate; prolonged by azole antifungals, HIV protease inhibitors, CCBs |
Key "Must-Know" Side Effects by Drug
| Drug | Most Distinctive / Exam-Important Side Effects |
|---|---|
| Phenytoin | Gingival hyperplasia, hirsutism, nystagmus/ataxia (dose-toxic), lymphadenopathy, teratogenicity, nonlinear (zero-order) kinetics - small dose increments cause large toxicity |
| Phenobarbitone | Sedation (adults) / hyperactivity (children), cognitive impairment, tolerance and dependence, enzyme induction, osteoporosis, megaloblastic anaemia |
| Carbamazepine | Aplastic anaemia/agranulocytosis, Stevens-Johnson syndrome, hepatitis, hyponatremia (SIADH), diplopia/ataxia, teratogenicity (spina bifida) |
| Sodium Valproate | Hepatotoxicity (fatal in children <2 yrs), neural tube defects (highest teratogenic risk), weight gain, alopecia, tremor, pancreatitis (rare), bone marrow suppression |
| Midazolam | Respiratory depression (potentiated by opioids), apnea, amnesia, paradoxical agitation in elderly, delirium, prolonged effect with CYP3A4 inhibitors; reversible with flumazenil |
Sources:
- Harrison's Principles of Internal Medicine, 22nd Ed., Table 436-9 (Antiepileptic Drug Adverse Effects)
- Kaplan & Sadock's Synopsis of Psychiatry, pp. 2001-2024 (Carbamazepine, Phenytoin sections)
- Adams & Victor's Principles of Neurology, 12th Ed., Chapter 15 (Specific Drugs in Seizure Treatment)
- Goldman-Cecil Medicine, MIDAZOLAM section
- Barash, Cullen & Stoelting's Clinical Anesthesia, 9th Ed., Benzodiazepines chapter
Clinical Note: Sodium valproate carries the highest teratogenic risk among all five drugs and should be avoided in women of childbearing age whenever possible. Midazolam is the only drug in this list that is reversible with a specific antagonist (flumazenil).
This is a shared conversation. Sign in to Orris to start your own chat.